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The association of tuberculosis (TB) with human immunodeficiency virus (HIV) infection 
and acquired immune deficiency syndrome over the past several years has become an 
emerging syndemic. Approximately 10% of people living with HIV (PLHIV) with latent TB 
infection will develop active TB disease each year. In this review, we highlight that this 
phenomenon is not limited to high endemic regions, such as Afro-Asian nations, but 
globalization/migration is causing increased case detection even in developed nations, 
such as the United States. Active screening should be performed for TB in PLHIV. A high 
degree of clinical suspicion for TB is warranted in PLHIV presenting with fever, cough, 
and unintentional weight loss. HIV–Mycobacterium tuberculosis (MTB) coinfection is 
often paucibacillary, precluding diagnosis by conventional diagnostics and/or smear 
microscopy/culture. Improved detection of pulmonary and extrapulmonary TB is now 
possible by incorporation of the GeneXPERT MTB/RIF assay (Cepheid Inc., Sunnyvale, 
CA, USA). The World Health Organization recommends instituting immediate therapy for 
MTB, in conjunction with ongoing or newly introduced anti-retroviral therapy. Vigilance 
is required to detect drug-induced organ injuries, and early-treatment-induced immune 
reconstitution inflammatory syndrome. Collaborating MTB and HIV activities in concen-
trated HIV epidemic settings should become a high public health priority.
Keywords: coinfections, extrapulmonary tuberculosis, Hiv, TB, diagnosis, GeneXpert, AFB
inTRODUCTiOn
Mycobacterium tuberculosis (MTB) coinfection in patients pre-infected with human immunode-
ficiency virus (HIV) and/or with full-blown acquired immune deficiency syndrome (AIDS) is an 
emergent pandemic (1–3). Due to increased recognition of the morbidity and mortality associated 
with this coinfection, the World Health Organization (WHO) recommends aggressive approaches 
for MTB screening during primary visits related to HIV screening and treatment (2). While this 
state of coinfection is a major public health challenge in resource-constrained settings with a high 
burden of both diseases, such as those in African and Asian nations (1, 4, 5), it is being increasingly 
recognized in the settings of developed nations, including the United States (U.S.) (6–9). WHO 
estimated 1.5 million tuberculosis (TB) deaths in approximately 70% HIV-negative and 30% HIV-
positive individuals, which makes MTB the second leading cause of death from an infectious disease 
and the leading cause of death in the setting of AIDS worldwide (10). This review presents the key 
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clinical aspects of HIV–MTB coinfection, including the uncom-
mon presentations, diagnostic issues, and management strategies, 
and emphasizes the continued need for increased vigilance for 
intensified case finding.
Per WHO guidelines, all clients attending HIV testing centers 
and people living with HIV (PLHIV) attending anti-retroviral 
therapy (ART) centers should be clinically screened for TB 
symptoms at every ambulatory encounter (2). Although the 
initiation rates of HIV-positive TB patients to ART are improving 
case fatality continues to be steep compared to HIV-negative TB 
patients (2). The chief rationale for this difference may include 
delays in bacteriological detection of HIV-associated TB, enroll-
ment into ART care or immediacy of ART initiation (2).
Different populations pose group-specific challenges in 
response to detection and treatment. These populations include 
pediatric patients, antenatal HIV-infected patients, truckers, 
female sex workers, and men who have sex with men, refugees, 
and displaced populations (2). Other challenges exist in over-
crowded settings such as mines, prisons, homeless shelters, and 
opioid substitution therapy centers (2). Social issues, including 
poverty, are warped into the fabric of clinical course of HIV–MTB 
coinfection (2). In this review, we emphasize early detection by 
effective implementation of provider-initiated HIV testing and 
counseling in TB patients as well as intensified TB case finding 
among PLHIV and initiation of prompt treatment to minimize 
morbidity and mortality (2).
DeMOGRAPHiC FACTORS ReLATeD TO 
MYCOBACTERIUM TUBERCULOSIS 
COinFeCTiOn in Hiv PATienTS
Gender, age, socioeconomic status, marital status, and educa-
tional level are factors that impact the likelihood of HIV–MTB 
coinfection. Male gender is reported to be positively correlated 
with MTB infection at a ratio of 2:1 (11). HIV–MTB coinfection 
is more common in adults with an average age of 33–45  years 
(2). Single status, low socioeconomic and income status, and lack 
of education are associated with disadvantaged living conditions. 
Compromised sanitation and poor access to healthcare negatively 
impact outcomes, which may explain the higher incidence and 
mortality in this group of patients (2).
It is important to outline some exceptions here. For example, 
young people may also be afflicted with the coinfection. Pediatric 
populations may particularly be at high risk, especially those who 
acquired infections by vertical transmission (12). Interestingly, 
certain geographic regions such as the Pakistan–Afghanistan 
border areas report more incidence in females than males (13). 
According to the WHO 2013 Global TB Report, Afghanistan is 
a high burden country for TB with a male to female ratio for 
TB of 0.5, so that in contrast to many other countries, Afghan 
women are more likely to be infected with TB than men. The 
estimated incidence of HIV–TB coinfections is relatively low 
(1 in 100,000) in this group and concentrated mostly among 
injection drug users (according to the World Bank). If there was 
a higher HIV–MTB coinfection incidence in Afghan women 
refugees, the observations would likely be due to the higher 
TB incidence in Afghan women or due to a small sample size 
of HIV–MTB coinfection in a refugee camp. Furthermore, 
immunocompromised states, such as those receiving anti-tumor 
necrosis factor treatment, corticosteroids, dialysis, organ, or 
hematologic transplantation or those with silicosis, may be more 
predisposed to HIV–MTB coinfection due to activation of latent 
TB infection (14).
PATHOGeneSiS OF MYCOBACTERIUM 
TUBERCULOSIS–Hiv COinFeCTiOn
The details of immune responses to TB, HIV, and coinfections 
have been described in recent reviews (1, 15). It is important 
to note that MTB occurs earlier in HIV patients than other 
opportunistic infections (OIs) due to increased susceptibility of 
MTB-specific CD4+ T-cells to HIV infection (16). We present the 
immune pathogenesis in relation to the intensity of the clinical 
presentation of TB with pre-existing HIV infection.
Tuberculosis infection is a result of the interplay between bac-
terial virulence and host resistance (17, 18). The infection begins 
through inhalation of air droplets containing approximately 
1–200 bacilli from an individual with active MTB (pulmonary) 
disease (18). The bacilli are rapidly phagocytosed by resident 
macrophages in the alveoli. This triggers an inflammatory cas-
cade, followed by development of granuloma. Furthermore, cell-
mediated immunity through activation of CD4–T lymphocytes 
is important in the prevention of MTB disease’s acceleration and 
reactivation (1, 15, 17, 18).
On the other hand, HIV transmitted primarily through genital 
fluids, blood, and mucosa interacts with different cells in the 
body and tends to escape the host immune response against it, 
resulting in full-blown AIDS disease (19). Progression of HIV 
infection is a result of a combination of CD4+ T lymphocytes 
depletion and a chronic state of immune inactivation. The repres-
sion of CD4+ T cells and impairment of macrophages’ activity 
in HIV/AIDS results in down-regulation of the body’s immune 
response to infections, such as MTB. Mycobacteria are contained 
within granulomas; however, their disruption leads to MTB 
bacterial growth and systemic dissemination to multiple organs 
(1, 15). MTB has a negative impact on the immune response of 
the body to HIV by up-regulating the immune response of the 
host by activating T-cells. Studies have demonstrated that MTB 
enhances HIV viral replication by increasing the expression of 
receptors (e.g., CXCR4), which favors viral growth (15, 19). The 
immune response is responsible for the vigor of TB infection in a 
HIV-coinfected host and is responsible for miliary and extrapul-
monary presentations and its associated diagnostic dilemma (1, 
15, 20, 21).
Studies aiming to obtain direct evidence of disease progres-
sion have been limited due to economic reasons of HIV viral 
load estimation, especially in countries where the incidence/
prevalence of HIV–MTB coinfection is high but has the short-
coming of resource constraints (22). As pointed out, the impact of 
MTB on HIV disease progression primarily involves upregulated 
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HIV-1 viral load, including the development of new OIs (22–28). 
Interestingly, TB was found to exert significant effect on diminish-
ing survival rates in subjects with more preserved immunological 
status (i.e., CD4 cell counts >200  cells/μL) (27, 28). Enhanced 
HIV-1 production has been demonstrated at local sites of MTB 
infection, for example, in bronchoalveolar lavage (BAL) fluid from 
TB involved, compared with uninvolved, lungs of patients with 
HIV-1/TB coinfection (29). A clinical presentation of TB that is 
particularly observed in HIV-1-infected patients is pleural TB, 
a common presentation in African coinfected patients (30, 31). 
These sites of active MTB infection act as foci of HIV replication 
and evolution of quasi-species, independent of systemic HIV-1 
activity, and may be responsible for disseminated MTB infection 
in HIV-1 coinfected hosts.
Mycobacterium tuberculosis breaches the alveolar epithe-
lium during the first phase of extrapulmonary dissemination. 
Molecular mechanisms for this cytolysis have been reported. 
For example, heparin-binding hemagglutinin adhesin (HBHA) 
facilitates MTB to bind to sulfated glycoconjugates on epithelial 
cells. Two gene products of the MTB RD1 gene, early secretory 
antigenic target 6  kDa (ESAT-6) and culture filtrate protein 
10 kDa (CFP-10), have been causally linked to the cell lysis and 
extrapulmonary mycobacterial spread (32). The trafficking of 
mycobacteria to the regional lymph nodes, while essential for the 
development of a protective T-cell-mediated immune response, is 
the first extrapulmonary site of migration of MTB. Bacteria there-
after disseminated through the bloodstream and lymphatics lead 
to extrapulmonary tuberculosis (EPTB). Lung granulomas from 
MTB/HIV-1 coinfected patients release lower levels of in  situ 
TNF production (33). Additionally, MTB–HIV-1 coinfected 
hosts have low circulating mannose-binding lectin levels (34). 
The complex interactions that take place between host T cells, 
Tregs, cytokine production, and overall impaired Th1 responses 
predispose to extrapulmonary infections in HIV-coinfected 
hosts (35, 36). Several primary immunodeficiencies, including 
Mendelian susceptibility to mycobacterial infections, enhance 
the overall risk of EPTB (37). These aspects merit detailed studies 
in the future.
SCReeninG FOR MYCOBACTERIUM 
TUBERCULOSIS–Hiv COinFeCTiOn
World Health Organization formulated a policy on collabora-
tive MTB/HIV activities with the chief aim to reduce the dual 
burden of MTB and HIV (2). WHO recommends MTB screen-
ing among HIV-positive patients at the time of diagnosis and 
before the initiation of ART. The screening for MTB should 
also be extended to the household contacts of HIV-positive 
patients (2). The screening tool utilizes a clinical symptom-
based algorithm that consists of the absence or presence of 
current cough, fever, weight loss, or night sweats at the time 
of initial presentation and at every visit to health clinics. 
This tool can be used to identify patients who need further 
medical attention and those who need MTB chemoprophylaxis 
intended to prevent active TB disease (rather than prevention 
of TB infection per se).
DiAGnOSiS OF MYCOBACTERIUM 
TUBERCULOSIS inFeCTiOn in Hiv-
COinFeCTeD PATienTS
A high degree of clinical suspicion and the need for obtaining a 
focused and detailed history merits emphasis. Numerous diseases 
may mimic presentations of TB, but TB should be high up on 
the differential for pneumonic presentations and HIV-associated 
thoracic diseases (7, 38). Initial screening with a tuberculin skin 
test (TST) or interferon-gamma release assays (IGRA) is recom-
mended. TST, which can be affected by bacillus Calmette–Guérin 
(BCG) vaccination, and/or IGRA, which is unaffected by BCG 
vaccination, are routinely used screening methods for TB in 
asymptomatic, non-HIV-infected individuals in low TB preva-
lence nations. However, it may be noted that these tests have a 
“low specificity” (TST) or “have false positive and false negative 
results” (IGRA) and are of low diagnostic values in TB endemic 
areas, especially when there is coinfection with HIV. When there 
is a high degree of clinical suspicion or pneumatic presentations, 
the standard diagnosis of TB in symptomatic patients is typically 
not a TST or IGRA, but rather achieved with sputum smear 
microscopy. This is inexpensive, rapid, and easy to perform in a 
field setting but has a lower sensitivity in MTB–HIV coinfection. 
The sputum smear sample has the advantage of being used for 
culture of MTB and drug susceptibility testing. Because coinfec-
tion lowers microscopy sensitivity, several current diagnostic 
techniques are more sensitive than the conventional sputum 
smear microscopy in detecting MTB in HIV-positive individu-
als. A growth-based detection of MTB, in cultures and molecular 
techniques, such as nucleic acid amplification testing (NAAT), 
has been shown to be more sensitive and allows strain characteri-
zation and drug susceptibility tests (39, 40).
In 2013, the Food and Drug Administration (FDA) in the 
U.S. approved the GeneXpert MTB/RIF assay (Cepheid Inc., 
Sunnyvale, CA, USA), a NAAT-based diagnostic platform. 
WHO endorsed the use of this assay as the initial test for 
TB diagnosis in PLHIV or who are suspected of multidrug-
resistant TB (MDR-TB) and has since been extensively used 
(41–44). The cost of the test, despite being subsidized, has been 
a barrier in many TB endemic countries to be used as a first line 
diagnostic tool.
Additionally, low thresholds should be exercised when per-
forming standard chest X rays and computerized tomography 
scans for diagnostic suspicion of miliary TB and detecting lesions 
during extrapulmonary manifestations (38). The pleomorphic 
manifestations of radiographic appearances in HIV–MTB coin-
fection is depicted in Figure 1.
A critical caveat in the diagnosis of MTB relates to the 
context of latent TB. The low specificity of TST and the issues 
of false positive and false negative detection with IGRA’s 
[QuantiIFERON®-TB Gold In-Tube (QFT-G-IT) assay (Cellestis 
Ltd., Carnegie, VIC, Australia) or T-SPOT®TB assay (Oxford 
Immunotec Inc., Marlborough, MA, USA)] pose significant chal-
lenges in HIV-coinfected patients. The critical aspects and unmet 
needs in diagnosing latent TB have been recently reviewed (39). 
Due to very high risk of activation of latent TB in HIV coinfection, 
FiGURe 1 | Chest radiographic appearances of tuberculosis in Hiv. (A) Right hilar lymphadenopathy and bronchial markings in a primary pulmonary 
tuberculosis-like presentation in a HIV-infected young adult (B) Left lower lobe consolidation due to Streptococcus pneumonia infection in pre-existing tuberculosis 
and HIV coinfections (Ci,ii) Radiologic appearance of IRIS. Chest X-ray showing radiographic progression of a small left lobar lesion to widespread consolidation of 
a tuberculosis patient few weeks after initiating anti-retroviral therapy (ART). All CXRs obtained from permission with Chou et al. (38).
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these cohorts (immunocompromised subjects, immigrants from 
countries with high disease burden, homeless subjects, prison-
ers, illicit drug users, healthcare workers taking care of high risk 
group populations, and adult contacts of persons with TB) need 
careful identification and evaluation to be considered for follow-
up, preventive therapy, and prompt institution of treatment upon 
detection of active lesions.
CLiniCAL MAnAGeMenT OF 
MYCOBACTERIUM TUBERCULOSIS–Hiv 
COinFeCTiOn
Delay in the diagnosis of MTB in HIV-positive patients and 
inadequate initial treatment may lead to multidrug resistant TB 
(MDR-TB). MDR-TB is a growing concern not only because of 
its longer treatment duration but also because of its associated 
increased transmission risk among contacts and increased mor-
tality rates in HIV-coinfected patients (45).
Considerations in the management of HIV–MTB coinfection 
include adjustment in the duration, dosage, and frequency of 
anti-TB drug administration as well as optimal timing of initia-
tion of highly active anti-retroviral therapy (HAART) treatment. 
The standard therapeutic regimen for TB consists of isoniazid 
(INH), a rifamycin (rifampin-RIF or rifabutin-RFB), pyrazina-
mide (PZA), and ethambutol (EMB) given for 2 months, followed 
by INH plus rifamycin for 4–7 months (46). Treatment of active 
TB infection is the priority due to the risk of transmitting TB 
to other people. However, when CD4+ T cell count is extremely 
low (<50  cells/mm3), an appropriate treatment plan should be 
formulated wherein prompt initiation of HAART is necessary. 
Randomized controlled trials such as SAPiT (47), CAMELIA 
(48), and STRIDE (49) suggested and have provided evidence 
for immediate institution of ART within 2 weeks of starting anti-
mycobacterial therapy.
There are several debates on the ideal timing of HAART initia-
tion and concomitant administration with anti-TB medications. 
Advantages of early HAART administration include higher cure 
December 2015 | Volume 3 | Article 2815
Montales et al. HIV–MTB/AIDS Coinfection
Frontiers in Public Health | www.frontiersin.org
rates, reduced risk of relapse, reduced risk of infection with other 
HIV-associated OIs, and lower mortality rates. On the other hand, 
disadvantages include potential drug interactions of HAART with 
rifampicin, thus limiting co-administration of selected protease 
inhibitors (PIs), cumulative toxicity, therapeutic failure, and the 
risk of immune reconstitution inflammatory syndrome (IRIS), 
which affect the long-term adherence to HAART in MTB-infected 
patients (50). Furthermore, non-compliance due to pill burden, 
side effects of medications, accessibility of treatment centers for 
HIV and TB, fears of stigmatization, cost of healthcare, and lack of 
proper health education are also major problems that need to be 
addressed to successfully treat MTB patients (51). In general, the 
priority should be to provide directly observed therapy (DOT) for 
these patients to ensure compliance and treatment success (10). 
Two recently published trials have re-emphasized the importance 
of early initiation of ART. The TEMPRANO study from the Ivory 
Coast showed that early ART initiation in subjects with CD4+ cell 
count of ≥500 cells/mm3 was associated with a 44% lower risk of 
death or severe HIV-related illness than when ART was initiated 
according to prevailing WHO criteria (52). Furthermore, patients 
who received INH prophylaxis had a 35% lower risk of death or 
severe HIV-related illness than patients who did not receive it. 
In the START study involving 215 sites in 35 countries, the risk 
of death, a serious AIDS-related event, or a serious non-AIDS-
related event was 57% less among the subjects treated early than 
among those treated when the CD4+ cell count decreased to 
350 cells/mm3 (53). In both trials, a reduced rate of TB after early 
rather than deferred ART was the most significant contributor to 
the overall benefits. Early initiation of ART possesses the added 
benefits of reducing the risk of sexual transmission of HIV and 
HSV2 infections (54). However, the public health challenges 
concerning the cost and global health motivation for implemen-
tation of these recent evidence-based guidelines remains a major 
challenge that needs to be overcome (54).
In specific patients, such as HIV-infected pregnant women 
with active TB, the recommendation is to start on ART as early 
as feasible, both for maternal health and to prevent perinatal 
transmission of HIV (55). The choice of ART should be based on 
efficacy and safety in pregnancy and take into account potential 
drug interactions between anti-retrovirals and rifamycin (50). In 
HIV-infected patients with latent tuberculosis infection (LTBI), 
isoniazid preventive therapy (IPT) has been reported to reduce 
reactivation of latent TB infection in the context of both indus-
trialized and developing countries (56).
COMPLiCATiOnS ARiSinG OUT OF 
THeRAPY FOR Hiv–MTB COinFeCTiOn
immune Reconstitution inflammatory 
Syndrome
Transient exacerbation of respiratory signs and symptoms despite 
reduction in viral load and/or radiological deterioration may 
develop in HIV–MTB coinfected patients who are treated with 
anti-TB medications concomitantly with HAART (19). IRIS has 
a dimorphic presentation: unmasking and paradoxical (57, 58). 
Restoration of immune competence by administration of ART 
results in hyperimmune host response to TB bacilli and/or anti-
gens. Unmasking IRIS presents with active TB soon after ART is 
started. Paradoxical IRIS refers to the worsening of TB symptoms 
after ART is initiated in patients who are receiving TB treatment. 
Anti-inflammatory drugs and steroids are the mainstay therapy 
for IRIS. Discontinuation of HAART is not warranted in most 
cases. Delaying initiation of ART for 2–8 weeks may reduce the 
incidence and severity of IRIS. However, this possible advantage 
of delayed ART must be weighed against the potential benefit 
of earlier ART in improving immune function and preventing 
progression of HIV disease and mortality. Importantly, immune 
reconstitution with ART may result in unmasking LTBI (i.e., con-
version of a previously negative TST to a positive TST or a positive 
IGRA for MTB-specific proteins) (44). A positive IGRA, similar 
to a positive TST, is indicative of LTBI in the absence of evidence 
of active TB disease. Because treatment for LTBI is indicated in 
the absence of evidence of active TB disease, this situation should 
be clinically recognized, especially in high risk groups.
Anti-Tuberculosis and Anti-Retroviral Drug 
interaction
Rifamycins are potent inducers of the hepatic cytochrome P 
(CYP) 450 enzyme. They are associated with significant interac-
tions with all PIs, some non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), maraviroc (MVC), and raltegravir (RAL) 
(50, 58–61), leading to enhanced drug clearance and significant 
lowering in circulating anti-retroviral drugs. However, good viro-
logical, immunological, and clinical outcomes may be achieved 
with standard doses of efavirenz (EFV) and nevirapine (NVP) 
when combined with rifampin (61). Suboptimal HIV suppres-
sion or suboptimal response to TB treatment should prompt 
immediate assessment of drug adherence, sub-therapeutic drug 
levels (with consideration for therapeutic drug monitoring), and 
acquired drug resistance.
Other Known Side effects
Hepatotoxicity potentially arises from co-administration of anti-
retroviral and anti-mycobacterial agents; therefore, continuous 
monitoring of liver function should be exercised. Symptoms of 
abdominal pain, jaundice, loss of appetite, fever, and nausea merit 
urgent clinical attention (39). Additionally, many of these patients 
may need additional treatment, for example, for drug dependence 
or HCV coinfection, which presents additional risk for coexisting 
liver diseases (62). Peripheral neuropathy, on the other hand, can 
occur with administration of INH, didanosine (ddI), or stavudine 
(d4T) or may be a manifestation of the native HIV infection per se. 
All patients receiving INH should be administered supplemental 
pyridoxine to reduce peripheral neuropathy (61). Other coexist-
ing medical and behavioral conditions, such as tobacco smoking, 
alcoholism, malnutrition, and diabetes mellitus, may significantly 
impact disease management and outcomes (63).
COnCLUSiOn
Coinfection with the HIV is an important contributing factor 
to TB mortality not only in many countries, mainly those of 
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sub-Saharan Africa, but also in developed countries such as 
the U.S. Today, caring for TB patients and controlling the 
spread of TB are complicated by the emergence of MDR-TB. 
Globalization and migration from endemic zones continues 
to be a major force in global spread of this coinfection. 
HIV-infected patients with active TB disease should receive 
treatment support, including adherence counseling and DOT, 
corresponding to their needs. In conclusion, MTB and HIV 
coinfection remains a diagnostic and therapeutic challenge 
worldwide.
ReFeRenCeS
1. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis 
and HIV co-infection. PLoS Pathog (2012) 8(2):e1002464. doi:10.1371/
journal.ppat.1002464 
2. World Health Organization. Global Tuberculosis Report. Geneva: World 
Health Organization (2013).
3. Montales MT, Beebe A, Chaudhury A, Patil N. Mycobacterium tuberculosis 
infection in a HIV-positive patient. Respir Med Case Rep (2015) 16:160–2. 
doi:10.1016/j.rmcr.2015.10.006 
4. Efsen AM, Schultze A, Post F, Panteleev A, Furrer H, Miller R, et al. Major 
challenges in clinical management of TB/HIV co-infected patients in Eastern 
Europe compared with Western Europe and Latin America. J Int AIDS Soc 
(2014) 17(4 Suppl 3):19505. doi:10.7448/IAS.17.4.19505 
5. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, 
et  al. TBNET. Risk assessment of tuberculosis in immunocompromised 
patients. A TBNET study. Am J Respir Crit Care Med (2014) 190(10):1168–76. 
doi:10.1164/rccm.201405-0967OC 
6. Hotez PJ. Blue marble health and “the big three diseases”: HIV/AIDS, 
tuberculosis, and malaria. Microbes Infect (2015) 17(8):539–41. doi:10.1016/j.
micinf.2015.05.004 
7. Khabbaz RF, Moseley RR, Steiner RJ, Levitt AM, Bell BP. Challenges of 
infectious diseases in the USA. Lancet (2014) 384(9937):53–63. doi:10.1016/
S0140-6736(14)60890-4 
8. Patil N, Marco A, Saba H, Samant R, Mukasa L. TB or not TB; don’t miss the 
obvious. J Ark Med Soc (2014) 111(6):112–4. 
9. Berzkalns A, Bates J, Ye W, Mukasa L, France AM, Patil N, et al. The road 
to tuberculosis (Mycobacterium tuberculosis) elimination in Arkansas; a 
re-examination of risk groups. PLoS One (2014) 9(3):e90664. doi:10.1371/
journal.pone.0090664 
10. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, 
et  al. The growing burden of tuberculosis: global trends and interactions 
with the HIV epidemic. Arch Intern Med (2003) 163:1009–21. doi:10.1001/
archinte.163.9.1009 
11. Holmes C, Hausler H, Nunn P. A review of sex differences in the epidemiology 
of tuberculosis. Int J Tuberc Lung Dis (1998) 2(2):96–104. 
12. Venturini E, Turkova A, Chiappini E, Galli L, de Martino M, Thorne C. 
Tuberculosis and HIV co-infection in children. BMC Infect Dis (2014) 
14(Suppl 1):S5. doi:10.1186/1471-2334-14-S1-S5 
13. Available from: http://www.who.int/tb/publications/tb_women_fact-
sheet_251013.pdf, 2014.
14. Richeldi L, Losi M, D’Amico R, Luppi M, Ferrari A, Mussini C, et  al. 
Performance of tests for latent tuberculosis in different groups of immu-
nocompromised patients. Chest (2009) 136(1):198–204. doi:10.1378/
chest.08-2575 
15. Shankar EM, Vignesh R, Ellegård R, Barathan M, Chong YK, Bador 
MK, et  al. HIV-Mycobacterium tuberculosis co-infection: a ‘danger-cou-
ple model’ of disease pathogenesis. Pathog Dis (2014) 70(2):110–8. 
doi:10.1111/2049-632X.12108 
16. Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Reither K, Heeregrave EJ, 
et al. Preferential infection and depletion of Mycobacterium tuberculosis-spe-
cific CD4 T cells after HIV-1infection. J Exp Med (2010) 207(13):2869–81. 
doi:10.1084/jem.20100090 
17. Scaling Up of Collaborative TB/HIV Activities in Concentrated HIV 
Epidemic Settings. A Case Study from India. World Health Organization 
(2015). Available from: http://www.who.int/tb/publications/
india_case_study_document_page/en/
18. Cooper A. Cell mediated immune responses in tuberculosis. Annu Rev 
Immunol (2009) 27:393–422. doi:10.1146/annurev.immunol.021908.132703 
19. Saharia KK, Koup RA. T cell susceptibility to HIV influences outcome 
of opportunistic infections. Cell (2013) 155(3):505–14. doi:10.1016/j.
cell.2013.09.045 
20. Moir S, Chun T, Fauci A. Pathogenic mechanisms of HIV disease. Annu Rev 
Pathol (2011) 6:223–48. doi:10.1146/annurev-pathol-011110-130254 
21. Diedrich C, Flynn J. HIV-1/Mycobacterium tuberculosis co-infection 
immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun (2011) 
79(4):1407–17. doi:10.1128/IAI.01126-10 
22. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease 
progression and prognosis during concurrent HIV/TB infection. Int J Infect 
Dis (2007) 11(4):289–99. doi:10.1016/j.ijid.2007.02.001 
23. Wolday D, Hailu B, Girma M, Hailu E, Sanders E, Fontanet AL. Low CD4+ 
T-cell count and high HIV viral load precede the development of tuberculosis 
disease in a cohort of HIV-positive Ethiopians. Ethiop Med J (2003) 41(Suppl 
1):67–73. 
24. Kaplan JE, Hanson DL, Jones JL, Dworkin MS; Adult and Adolescent 
Spectrum of HIV Disease Project Investigators. Viral load as an independent 
risk factor for opportunistic infections in HIV-infected adults and adolescents. 
AIDS (2001) 15(14):1831–6. doi:10.1097/00002030-200109280-00012 
25. Swindells S, Evans S, Zackin R, Goldman M, Haubrich R, Filler SG, et al. Predictive 
value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune 
Defic Syndr (2002) 30(2):154–8. doi:10.1097/00042560-200206010-00003 
26. Toossi Z. Virological and immunological impact of tuberculosis on human 
immunodeficiency virus type 1 disease. J Infect Dis (2003) 188(8):1146–55. 
doi:10.1086/378676 
27. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. 
Accelerated course of human immunodeficiency virus infection after 
tuberculosis. Am J Respir Crit Care Med (1995) 151(1):129–35. doi:10.1164/
ajrccm.151.1.7812542 
28. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. 
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune 
activation. J Immunol (1996) 157(3):1271–8. 
29. Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S, Cao Y, et  al. 
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 
replication in the lung. Am J Respir Crit Care Med (1997) 155(3):996–1003. 
doi:10.1164/ajrccm.155.3.9117038 
30. Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, Peters P, et al. Increased 
replication of HIV1 at sites of Mycobacterium tuberculosis infection: potential 
mechanisms of viral activation. J Acquir Immune Defic Syndr (2001) 28(1):1–8. 
doi:10.1097/00042560-200109010-00001 
31. Frye MD, Pozsik CJ, Sahn SA. Tuberculous pleurisy is more common in AIDS 
than in non-AIDS patients with tuberculosis. Chest (1997) 112(2):393–7. 
doi:10.1378/chest.112.2.393 
32. Krishnan N, Robertson BD, Thwaites G. The mechanisms and consequences 
of the extra-pulmonary dissemination of Mycobacterium tuberculosis. 
Tuberculosis (Edinb) (2010) 90(6):361–6. doi:10.1016/j.tube.2010.08.005 
33. de Noronha AL, Báfica A, Nogueira L, Barral A, Barral-Netto M. Lung 
granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients 
display decreased in situ TNF production. Pathol Res Pract (2008) 204:155. 
doi:10.1016/j.prp.2007.10.008 
34. Garred P, Richter C, Andersen AB, Madsen HO, Mtoni I, Svejgaard A, et al. 
Mannan-binding lectin in the sub-Saharan HIV and tuberculosis epidemics. 
Scand J Immunol (1997) 46(2):204–8. doi:10.1046/j.1365-3083.1997.d01-111.x 
35. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF. T cell cytokine 
responses in persons with tuberculosis and human immunodeficiency virus 
infection. J Clin Invest (1994) 94:2435–42. doi:10.1172/JCI117611 
36. Berrington WR, Hawn TR. Mycobacterium tuberculosis, macrophages, and 
the innate immune response: does common variation matter? Immunol Rev 
(2007) 219:167–86. doi:10.1111/j.1600-065X.2007.00545.x 
December 2015 | Volume 3 | Article 2817
Montales et al. HIV–MTB/AIDS Coinfection
Frontiers in Public Health | www.frontiersin.org
37. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the 
human model. Annu Rev Immunol (2002) 20:581–620. doi:10.1146/annurev.
immunol.20.081501.125851 
38. Chou SH, Prabhu SJ, Crothers K, Stern EJ, Godwin JD, Pipavath SN. 
Thoracic diseases associated with HIV infection in the era of antiretroviral 
therapy: clinical and imaging findings. Radiographics (2014) 34(4):895–911. 
doi:10.1148/rg.344130115 
39. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium 
tuberculosis infection. N Engl J Med (2015) 372(22):2127–35. doi:10.1056/
NEJMra1405427 
40. World Health Organization. Improving the Diagnosis and Treatment of Smear-
Negative Pulmonary and Extrapulmonary Tuberculosis Among Adults and 
Adolescents: Recommendations for HIV-Prevalent and Resource-Constrained 
Settings (2006). Available from: http://www.who.int/tb/publications/2006/
tbhiv_recommendations.pdf
41. Kaul K. Molecular detection of Mycobacterium tuberculosis: impact on patient 
care. Clin Chem (2001) 47(8):1553–8. 
42. Patil N, Saba H, Marco A, Samant R, Mukasa L. Initial experience with 
GeneXpertMTB/RIF assay in the Arkansas tuberculosis control program. Aust 
Med J (2014) 7(5):203–7. doi:10.4066/AMJ.2014.1905 
43. Patil N, Montales MT, Mittadodla P, Mukasa LN, Bhaskar N, Bates JH, et al. 
Tuberculosis reinfection in a pregnant cystic fibrosis patient. Respir Med Case 
Rep (2015) 16:57–9. doi:10.1016/j.rmcr.2015.04.002 
44. Patil N, Marco A, Montales MT, Bhaskar N, Mittadodla P, Mukasa LN. 
Pulmonary tuberculosis in a patient with cystic fibrosis. North Am J Med Sci 
(2015) 7:233–5. doi:10.4103/1947-2714.157494 
45. Dean AS, Zignol M, Falzon D, Getahun H, Floyd K. HIV and multidrug-re-
sistant tuberculosis: overlapping epidemics. Eur Respir J (2014) 44(1):251–4. 
doi:10.1183/09031936.00205413 
46. Curran A, Falcó V, Pahissa A, Ribera E. Management of tuberculosis in HIV-
infected patients. AIDS Rev (2012) 14(4):231–46. 
47. Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, Gray AL, 
et al. Changes to antiretroviral drug regimens during integrated TB-HIV treat-
ment: results of the SAPiTtrial. Antivir Ther (2014) 19(2):161–9. doi:10.3851/
IMP2701 
48. Borand L, Pheng P, Saman M, Leng C, Chea P, Sarady Ay S, et al. [Tuberculosis 
and HIV co-infection: clinical trial under the coordination of the Institut 
Pasteur in Cambodia]. Med Sci (Paris) (2013) 29(10):908–11. doi:10.1051/
medsci/20132910020 
49. Crump JA, Wu X, Kendall MA, Ive PD, Kumwenda JJ, Grinsztejn B, et  al. 
Predictors and outcomes of Mycobacterium tuberculosis bacteremia among 
patients with HIV and tuberculosis co-infection enrolled in the ACTG 
A5221 STRIDE study. BMC Infect Dis (2015) 15(1):12. doi:10.1186/
s12879-014-0735-5 
50. Havlir DV, Currier JS. CROI 2015: complications of HIV infection and 
antiretroviral therapy. Top Antivir Med (2015) 23(1):56–65. 
51. Beebe A, Seaworth B, Patil N. Rifampicin-induced nephrotoxicity in a tuber-
culosis patient. J Clin Tuberc Other Mycobact Dis (2015) 1:13–5. doi:10.1016/j.
jctube.2015.09.001 
52. TEMPRANO ANRS 12136 Study Group; Danel C, Moh R, Gabillard D, 
Badje A, Le Carrou J, et  al. A trial of early antiretrovirals and isoniazid 
preventive therapy in Africa. N Engl J Med (2015) 373(9):808–22. doi:10.1056/
NEJMoa1507198 
53. INSIGHT START Study Group ; Lundgren JD, Babiker AG, Gordin F, 
Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymp-
tomatic HIV infection. N Engl J Med (2015) 373(9):795–807. doi:10.1056/
NEJMoa1506816 
54. Abdool Karim SS. Overcoming impediments to global implementation of 
early antiretroviral therapy. N Engl J Med (2015) 373(9):875–6. doi:10.1056/
NEJMe1508527 
55. van Lettow M, Bedell R, Mayuni I, Mateyu G, Landes M, Chan AK, et  al. 
Towards elimination of mother-to-child transmission of HIV: performance 
of different models of care for initiating lifelong antiretroviral therapy for 
pregnant women in Malawi (Option B+). J Int AIDS Soc (2014) 17:18994. 
doi:10.7448/IAS.17.1.18994 
56. Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid prophylactic therapy 
for the prevention of tuberculosis in HIV infected adults: a systematic review 
and meta-analysis of randomized trials. PLoS One (2015) 10(11):e0142290. 
doi:10.1371/journal.pone.0142290 
57. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory 
syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 
(2012) 10(2):150–6. doi:10.1038/nrmicro2712 
58. El-Sadr WM, Tsiouris SJ. HIV-associated tuberculosis: diagnostic and treat-
ment challenges. Semin Respir Crit Care Med (2008) 29(5):525–31. doi:10.10
55/s-0028-1085703 
59. Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in 
patients co-infected with HIV and Mycobacterium tuberculosis infections: 
focus on drug-drug interactions with rifamycins. Clin Pharmacokinet (2014) 
53(6):489–507. doi:10.1007/s40262-014-0144-3 
60. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, 
et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl 
J Med (2011) 365(16):1492–501. doi:10.1056/NEJMoa1014181 
61. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adoles-
cent-arv-guidelines/32/drug-interactions, 2013.
62. Getahun H, Baddeley A, Raviglione M. Managing tuberculosis in people 
who use and inject illicit drugs. Bull World Health Organ (2013) 91(2):154–6. 
doi:10.2471/BLT.13.117267 
63. Bates M, Marais BJ, Zumla A. Tuberculosis comorbidity with communicable 
and noncommunicable diseases. Cold Spring Harb Perspect Med (2015) 
5(11):a017889. doi:10.1101/cshperspect.a017889 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Montales, Chaudhury, Beebe, Patil and Patil. This is an 
open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
